Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity
Erin D. Lucas, Johnathon Schafer, Jennifer L. Matsuda, et al.
Cell Reports (2020) Vol. 33, Iss. 2, pp. 108258-108258
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 266
Emerging phagocytosis checkpoints in cancer immunotherapy
Yue Liu, Yanjin Wang, Yanrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 150
Immune checkpoint receptors in autoimmunity
Kelly P. Burke, Dillon G. Patterson, Dan Liang, et al.
Current Opinion in Immunology (2023) Vol. 80, pp. 102283-102283
Open Access | Times Cited: 41
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity
Colin Y. C. Lee, Bethany C. Kennedy, Nathan Richoz, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor
Kai Li, Avradip Chatterjee, Qian Chen, et al.
Nature (2024) Vol. 630, Iss. 8017, pp. 736-743
Closed Access | Times Cited: 11
Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization
Javier Fierro, Jake DiPasquale, Joshua Perez, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 30
Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jingyu Jiang, Haitao Huang, Ruihan Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Shanthi Ganesh, Min Ju Kim, Jenny Lee, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1895-1916
Open Access | Times Cited: 6
Afferent Lymphatic Transport and Peripheral Tissue Immunity
Maria M. Steele, Amanda W. Lund
The Journal of Immunology (2021) Vol. 206, Iss. 2, pp. 264-272
Open Access | Times Cited: 35
Efficient Photothermal, Flexible Wood-Based Hydrogel for Infected Wound Recovery
Lei He, Yongze Liu, Panpan Song, et al.
ACS Sustainable Chemistry & Engineering (2023) Vol. 11, Iss. 31, pp. 11529-11540
Closed Access | Times Cited: 14
Structure and Immune Function of Afferent Lymphatics and Their Mechanistic Contribution to Dendritic Cell and T Cell Trafficking
Jorge Arasa, Víctor Collado‐Díaz, Cornelia Halin
Cells (2021) Vol. 10, Iss. 5, pp. 1269-1269
Open Access | Times Cited: 32
PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration
Uma Kantheti, Tadg Forward, Erin D. Lucas, et al.
Science Advances (2025) Vol. 11, Iss. 5
Closed Access
Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
Stinne Ravn Greisen, M. Aspari, Bent Deleuran
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
Trafficking and retention of protein antigens across systems and immune cell types
Thu A. Doan, Tadg Forward, Beth A. Jirón Tamburini
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 5
Open Access | Times Cited: 16
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
Tao Wang, Desirée Denman, Silvia M. Bacot, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1181-1181
Open Access | Times Cited: 16
PD‐1: A critical player and target for immune normalization
Xuening Liu, Alison Zhao, Su Xiao, et al.
Immunology (2024) Vol. 172, Iss. 2, pp. 181-197
Open Access | Times Cited: 3
Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration
Min-Seon Song, Ji-Hee Nam, Kyung-Eun Noh, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-11
Open Access | Times Cited: 3
Role of IL-25 on Eosinophils in the Initiation of Th2 Responses in Allergic Asthma
Bo Peng, Lin Sun, Meng Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells
Anudari Letian, Eyoel Yemanaberhan Lemma, Paola Cavaliere, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 7
The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma
Cera Nieto, Bettina Miller, Nathaniel Alzofon, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 11, pp. 1392-1403
Open Access | Times Cited: 7
Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma
Minyu Wang, Lei Qin, Kevin Thia, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 10, pp. e009617-e009617
Open Access | Times Cited: 2
Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways
Keith L. Knutson
The Journal of Immunology (2024) Vol. 212, Iss. 9, pp. 1397-1405
Closed Access | Times Cited: 2
Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responses
Emily Bettini, Aleksey Chudnovskiy, Giulia Protti, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
Jonathan J. Hodgins, John Abou-Hamad, Colin Edward O’Dwyer, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 7
Closed Access | Times Cited: 2
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
Whitney Barham, Michelle A. Hsu, Xin Liu, et al.
ImmunoHorizons (2023) Vol. 7, Iss. 1, pp. 125-139
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top